Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lipid Regulators Market

Lipid Regulators Market Trends

Report ID: GMI8442
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Lipid Regulators Market Trends

Cardiovascular disease (CVD), including coronary artery disease, stroke, and peripheral artery disease, remains a leading cause of morbidity and mortality worldwide. For instance, according to World Health Organization, around 17.9 million people died from cardiovascular diseases which is almost 32% of all global deaths. Therefore, lipid regulators play a crucial role in managing cardiovascular diseases by targeting dyslipidemia, a major risk factor for CVD development and progression, thereby driving their demand in the market.
In addition to this, pharmaceutical companies are investing in the development of novel lipid regulators with improved efficacy, safety, and tolerability profiles. Emerging therapies, such as PCSK9 inhibitors offer additional treatment option for patients with difficult-to-treat hypercholesterolemia and cardiovascular diseases. Thus, increasing adoption of such treatments supports the market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for lipid regulators was valued at USD 32.4 billion in 2023 and is set to register 3.8% CAGR from 2024 to 2032, driven by the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, and growing awareness of the importance of lipid management in reducing cardiovascular risk.

The statins segment accounted for 60.1% market share in 2023 and is anticipated to record 4.1% CAGR from 2024 to 2032 as they are recommended as first-line therapy in treatment guidelines issued by organizations such as the American College of Cardiology (ACC).

North America market for lipid regulators accounted for USD 13.6 billion in 2023 and is projected to reach USD 18.1 billion by 2032, as the region faces a significant burden of cardiovascular disease.

AbbVie Inc, Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., Merck & Co., Novartis AG, Pfizer, Inc., Sanofi, and Teva Pharmaceuticals.